SCHEMBL864038

SCHEMBL864038

COCC(C)Nc1nc2c(Cl)cccc2cc1[C@H](C)Nc1ncnc2[nH]cnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 11/20 0.49
TP53 P04637 1/20 0.39
KRAS P01116 2/20 0.36
EGFR P00533 2/20 0.36
SOS1 Q07889 1/20 0.36
PIK3CG P48736 3/20 0.35
ABCB11 O95342 1/20 0.35
TBXA2R P21731 1/20 0.35
PIK3R1 P27986 1/20 0.35
HTR2A P28223 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PDE3A Q14432 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
AURKA O14965 1/20 0.34
RPS6KB1 P23443 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL865114 1.00 PIK3CD (0.49) PIK3CDTP53KRASEGFRSOS1
SCHEMBL864404 0.88 PIK3CD (0.48) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL864405 0.88 PIK3CD (0.48) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL864077 0.87 PIK3CD (0.47) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL864078 0.87 PIK3CD (0.47) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL863372 0.86 PIK3CD (0.54) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL863371 0.86 PIK3CD (0.54) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL863730 0.83 PIK3CD (0.47) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL863729 0.83 PIK3CD (0.47) PIK3CDKRASEGFRSOS1PIK3CG
SCHEMBL864804 0.83 PIK3CD (0.49) PIK3CDKRASEGFRSOS1PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396315-B1 QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-08-31 EP disclosed
US-8513284-B2 Fused pyridine and pyrazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2013-08-20 US disclosed
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors PDPK1, PDXK, PIK3CA PIK3CD 14/4885TP53 773/4885KRAS 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.